Literature DB >> 35177543

PET/MR Imaging in Evaluating Treatment Failure of Head and Neck Malignancies: A Neck Imaging Reporting and Data System-Based Study.

L D Patel1, K Bridgham1, J Ciriello1, R Almardawi1, J Leon1, J Hostetter1, S Yazbek1, P Raghavan2.   

Abstract

BACKGROUND AND
PURPOSE: PET/MR imaging is a relatively new hybrid technology that holds great promise for the evaluation of head and neck cancer. The aim of this study was to assess the performance of simultaneous PET/MR imaging versus MR imaging in the evaluation of posttreatment head and neck malignancies, as determined by its ability to predict locoregional recurrence or progression after imaging.
MATERIALS AND METHODS: The electronic medical records of patients who had posttreatment PET/MR imaging studies were reviewed, and after applying the exclusion criteria, we retrospectively included 46 studies. PET/MR imaging studies were independently reviewed by 2 neuroradiologists, who recorded scores based on the Neck Imaging Reporting and Data System (using CT/PET-CT criteria) for the diagnostic MR imaging sequences alone and the combined PET/MR imaging. Treatment failure was determined with either biopsy pathology or initiation of new treatment. Statistical analyses including univariate association, interobserver agreement, and receiver operating characteristic analysis were performed.
RESULTS: There was substantial interreader agreement among PET/MR imaging scores (κ = 0.634; 95% CI, 0.605-0.663). PET/MR imaging scores showed a strong association with treatment failure by univariate association analysis, with P < .001 for the primary site, neck lymph nodes, and combined sites. Receiver operating characteristic curves of PET/MR imaging scores versus treatment failure indicated statistically significant diagnostic accuracy (area under curve range, 0.864-0.987; P < .001).
CONCLUSIONS: Simultaneous PET/MR imaging has excellent discriminatory performance for treatment outcomes of head and neck malignancy when the Neck Imaging Reporting and Data System is applied. PET/MR imaging could play an important role in surveillance imaging for head and neck cancer.
© 2022 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35177543      PMCID: PMC8910793          DOI: 10.3174/ajnr.A7427

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  26 in total

1.  ACR Neck Imaging Reporting and Data Systems (NI-RADS): A White Paper of the ACR NI-RADS Committee.

Authors:  Ashley H Aiken; Tanya J Rath; Yoshimi Anzai; Barton F Branstetter; Jenny K Hoang; Richard H Wiggins; Amy F Juliano; Christine Glastonbury; C Douglas Phillips; Richard Brown; Patricia A Hudgins
Journal:  J Am Coll Radiol       Date:  2018-07-06       Impact factor: 5.532

2.  Simultaneous PET/MRI in assessing the response to chemo/radiotherapy in head and neck carcinoma: initial experience.

Authors:  Valeria Romeo; Brigida Iorio; Massimo Mesolella; Lorenzo Ugga; Francesco Verde; Emanuele Nicolai; Mario Covello
Journal:  Med Oncol       Date:  2018-06-19       Impact factor: 3.064

Review 3.  Use of PET in Head and Neck Cancers.

Authors:  Halil Erdem Özel
Journal:  Turk Arch Otorhinolaryngol       Date:  2015-06-01

4.  Positive Predictive Value of Neck Imaging Reporting and Data System Categories 3 and 4 Posttreatment FDG-PET/CT in Head and Neck Squamous Cell Carcinoma.

Authors:  P Wangaryattawanich; B F Branstetter; J D Ly; U Duvvuri; D E Heron; T J Rath
Journal:  AJNR Am J Neuroradiol       Date:  2020-05-28       Impact factor: 3.825

5.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

6.  Negative Predictive Value of NI-RADS Category 2 in the First Posttreatment FDG-PET/CT in Head and Neck Squamous Cell Carcinoma.

Authors:  P Wangaryattawanich; B F Branstetter; M Hughes; D A Clump; D E Heron; T J Rath
Journal:  AJNR Am J Neuroradiol       Date:  2018-08-30       Impact factor: 3.825

7.  MRI Posttreatment Surveillance for Head and Neck Squamous Cell Carcinoma: Proposed MR NI-RADS Criteria.

Authors:  M M Ashour; E A F Darwish; R M Fahiem; T T Abdelaziz
Journal:  AJNR Am J Neuroradiol       Date:  2021-03-11       Impact factor: 4.966

Review 8.  PET/MRI in Oncological Imaging: State of the Art.

Authors:  Usman Bashir; Andrew Mallia; James Stirling; John Joemon; Jane MacKewn; Geoff Charles-Edwards; Vicky Goh; Gary J Cook
Journal:  Diagnostics (Basel)       Date:  2015-07-21

9.  Diagnostic Accuracy and Confidence of [18F] FDG PET/MRI in comparison with PET or MRI alone in Head and Neck Cancer.

Authors:  Gi Jeong Cheon; Ji-Hoon Kim; Jisang Park; Kyoungjune Pak; Tae Jin Yun; Eun Kyoung Lee; Inseon Ryoo; Ji Ye Lee; Inpyeong Hwang; Roh-Eul Yoo; Koung Mi Kang; Seung Hong Choi; Chul-Ho Sohn
Journal:  Sci Rep       Date:  2020-06-11       Impact factor: 4.379

10.  Preliminary clinical results for PET/MR compared with PET/CT in patients with nasopharyngeal carcinoma.

Authors:  Yong Cheng; Le Bai; Jingjie Shang; Yongjin Tang; Xueying Ling; Bin Guo; Jian Gong; Lu Wang; Hao Xu
Journal:  Oncol Rep       Date:  2019-10-30       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.